Aligos Therapeutics (NASDAQ:ALGS) Stock Gets Downgrade from Wall Street Zen

Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday, Wall Street Zen reports.

ALGS has been the topic of several other research reports. Jefferies Financial Group initiated coverage on shares of Aligos Therapeutics in a research note on Monday, November 9th. They issued a “strong-buy” rating on the stock. Weiss Ratings lowered shares of Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 16th. Finally, HC Wainwright restated a “buy” rating on shares of Aligos Therapeutics in a research report on Monday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $38.50.

View Our Latest Research Report on ALGS

Aligos Therapeutics Stock Performance

Shares of NASDAQ:ALGS opened at $2.10 on Friday. The stock has a market capitalization of $13.12 million, a price-to-earnings ratio of -0.33 and a beta of 2.43. The stock’s 50-day simple moving average is $4.94 and its two-hundred day simple moving average is $6.03. Aligos Therapeutics has a 52-week low of $1.92 and a 52-week high of $13.69.

Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) last released its quarterly earnings results on Friday, November 6th. The company reported ($2.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.28) by $0.19. Aligos Therapeutics had a negative return on equity of 206.30% and a negative net margin of 197.01%. The business had revenue of $2.87 million during the quarter, compared to the consensus estimate of $4.85 million. As a group, equities analysts forecast that Aligos Therapeutics will post -6.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aligos Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ALGS. Bank of America Corp DE grew its stake in shares of Aligos Therapeutics by 1,652.8% during the 1st quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock valued at $1,707,000 after acquiring an additional 216,646 shares during the period. Renaissance Technologies LLC increased its holdings in Aligos Therapeutics by 17.6% in the 1st quarter. Renaissance Technologies LLC now owns 100,450 shares of the company’s stock worth $746,000 after acquiring an additional 15,006 shares in the last quarter. Finally, SummitTX Capital L.P. raised its stake in Aligos Therapeutics by 6.7% during the 1st quarter. SummitTX Capital L.P. now owns 148,799 shares of the company’s stock worth $1,106,000 after acquiring an additional 9,375 shares during the period. 60.43% of the stock is currently owned by hedge funds and other institutional investors.

About Aligos Therapeutics

(Get Free Report)

Aligos Therapeutics is a clinical-stage biopharmaceutical company based in South San Francisco, California. Founded in 2018, it focuses on developing medicines for viral infections and liver diseases. The company’s research has included investigational treatments for chronic hepatitis B and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Its development work has involved small-molecule drug candidates, including approaches intended to interfere with viral replication.

See Also

Analyst Recommendations for Aligos Therapeutics (NASDAQ:ALGS)

Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.